05.07.26 -- Lilly's Unified Mindset For A Global Parenteral And Device Manufacturing Network

AI-powered multiplexed imaging and analysis explore the tumor-immune microenvironment in colorectal adenocarcinoma, identifying potential biomarkers for therapeutic insights.

Potency assays for ATMPs demand precision. Learn how a matrix approach, regulatory alignment, and advanced technologies can overcome variability and ensure safety throughout the product lifecycle.

Transition from periodic sampling to continuous monitoring. Find out how to establish risk-based alert limits and use N:M trending to maintain a true state of control in critical cleanroom zones.

We discuss the trends in new molecular formats, which is one of the current drivers of renewed interest in fermentation technologies, along with some of their challenges. 

Gain insight into how leveraging a customs warehouse can streamline your supply chain, reduce VAT costs, and enhance global compliance and efficiency.

Use innovative lipid-based formulations and on-demand manufacturing to accelerate Phase 1 trials, enable flexible dose escalation, and maximize limited API for poorly soluble compounds.

Discover how understanding the transport phenomenon in the boundary layer can allow us to engineer the flow to manage the rate-limiting step and intensify the process.

A practical guide to applying Quality by Design to outsourced GXP operations, helping virtual and hybrid sponsors maintain regulatory control, inspection readiness, and accountability.

With each batch of cell and gene therapy product representing a wealth of lifesaving potential, this biopharma company needed the right packaging solution for its relatively new therapy applications.

Platform biotech companies face critical choices on partnering, licensing, or selling technology—decisions that shape focus, valuation, and long‑term success beyond scientific innovation alone.

The global market for injectable drugs will reach $69.13 billion by 2028. Examine the vital role of laminar airflow technology in meeting sterile integrity standards and minimizing contamination risks.

A sponsor’s commitment to rigorous impurity control throughout manufacturing is vital to ensuring patient safety. E&Ls, nitrosamines, and PFAS are among the most critical impurities to test for.

In the event of an IV bag leak, contaminants can adversely affect the solutions within. Uncover how the reference standard for CCIT, USP 1207, applies to the CCIT inspection method of IV bags.

Many tech transfer risks are avoidable with a single campus CDMO. With all manufacturing facilities on one site, drug sponsors can overcome obstacles and maintain speed en route to market.

See how pharma companies can select tailored pre-filled syringes for biologics and biosimilars by aligning drug delivery needs with specialized containers and analytical services.